A Druggable G Protein Checkpoint in Cholesterol Efflux

Key Points

GIV loss promotes macrophage cholesterol efflux, leading to reduced plaque burden and improved lipid profiles.
Inhibition of the GIV●Gαi checkpoint has shown effective cholesterol regulation in studies of lipid overload conditions.
Analysis highlights the G protein's role in mediating ABCA1 activity through both transcriptional and post-translational mechanisms.
These findings suggest new avenues for treatment strategies in immunometabolic diseases and highlight cholesterol management.

Abstract

Statins slow but rarely reverse plaque burden, leaving residual risk driven by LAM dysfunctionGIV (CCDC88A) non-canonically modulates Gαi to suppress macrophage cholesterol effluxGIV loss or inhibition restores ABCA1 activity via transcriptional and post-translational controlBlocking the GIV●Gαi checkpoint defats LAMs, regresses plaques, and relieves systemic lipid overloadIdentifies a druggable node that redefines RCT restoration as a therapeutic paradigm in immunometabolic disease.

A Druggable G Protein Checkpoint in Cholesterol Efflux

Key Points

Abstract

Cite This Study